Last reviewed · How we verify
Lialda
At a glance
| Generic name | Lialda |
|---|---|
| Sponsor | Warner Chilcott |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis (NA)
- Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease (PHASE2, PHASE3)
- Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine (NA)
- Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis. (NA)
- Desloratadine in Patients With Ulcerative Colitis (PHASE2)
- Determination of the Optimal Treatment Target in Ulcerative Colitis (PHASE4)
- Pentoxifylline in Patients With Ulcerative Colitis (PHASE2)
- Confirmatory Clinical Study in Active Ulcerative Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lialda CI brief — competitive landscape report
- Lialda updates RSS · CI watch RSS
- Warner Chilcott portfolio CI